Back to search results

Comparing Sarecycline and Doxycycline for Acne and Gut Bacteria

This study is looking at how two common acne medications, Sarecycline and Doxycycline, affect the bacteria in your gut and on your skin. Researchers want to understand if these treatments change the types of bacteria present. You may be able to join if you have acne vulgaris with at least 10 inflammatory lesions (red bumps or pimples) and no more than 2 nodules (larger, deeper bumps) on your face. The study will measure changes in specific bacteria in your gut after 4 weeks of treatment. The current recruitment status is unclear, but the study plans to enroll 30 participants.

Study design
This study is an interventional trial planning to enroll 30 participants. It compares the effects of Sarecycline and Doxycycline.
What's involved
You would take either Sarecycline or Doxycycline by mouth once or twice a day with food and water. The study will involve measurements of your gut bacteria from enrollment to the end of treatment at 4 weeks.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed from enrollment to the end of treatment at 4 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07544251

Comparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne.

Recruiting
PHASE4Ages 9+InterventionalTreatment
Integrative Skin Science and Research
~30 participants
Updated 2026-04-22 on ClinicalTrials.gov
What's tested:SarecyclineDoxycycline

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in the relative abundance of tetracycline-resistant bacteria in the gut microbiome
Measured over From enrollment to the end of treatment at 4 weeks.
+1 more outcome measured

Conditions

Acne Vulgaris

Explore related trials

Acne

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Raja Sivamani, MD · PRINCIPAL_INVESTIGATOR · Integrative Skin Science and Research

Who to contact

Nasima Afzal Chief Operating Officer
[email protected]
916-775-5080
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

At least 10 inflammatory lesions (papules, pustules, and nodules) up to 100 noninflammatory lesions (open and closed comedones)
No more than 2 nodules on the face

Exclusion

Topical acne medications such as retinoids, antibiotics, hormonal modulators
Topical benzoyl peroxide
Topical anti-inflammatories and corticosteroids
Systemic antibiotics
Systemic acne treatments
Oral probiotic supplement
Systemic corticosteroids
Systemic retinoids

What this trial measures

  • Change in the relative abundance of tetracycline-resistant bacteria in the gut microbiomeFrom enrollment to the end of treatment at 4 weeks.

    Assessing change in the relative abundance of tetracycline resistant bacteria in the gut microbiome following treatment.

  • Change in the relative abundance of fungi/yeast in the gut microbiomeFrom enrollment to the end of treatment at 4 weeks.

    Assessing change in the relative abundance of fungi/yeast in the gut microbiome following treatment.